<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411331</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0232</org_study_id>
    <secondary_id>2014-A00488-39</secondary_id>
    <nct_id>NCT02411331</nct_id>
  </id_info>
  <brief_title>Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci</brief_title>
  <acronym>Etha-LOCK</acronym>
  <official_title>Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHG Jacques Lacarin (Vichy)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Henri Mondor (Aurillac)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Nord (Saint-Etienne)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH de Chambéry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de la Croix-Rousse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Implantable venous access port infections are mainly due to coagulase negative staphylococci
      and may be managed by antibiotic lock therapy with retention of the port. Most of the time a
      vancomycin lock is used. Experimental data show that vancomycin may be poorly effective in
      eradicating the staphylococcal biofilm in the port. Another disadvantage of
      Vancomycin-containing lock solution is the occurrence of resistant organisms and the risk of
      catheter occlusion. Ethanol-containing lock solution is highly effective in vitro and does
      not expose to the risk of emergence resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type of study: multi-center, randomized, double-blind, parallel-group, controlled clinical
      trial.

      Number of centers: 9 French centers in Auvergne and Rhône-Alpes regions

      Medical product Ethanol 40% + Enoxaparine 400UI/ml Versus Vancomycin 5 mg/ml + Héparine
      2500UI/ml

      Patients

      Patients eligible for inclusion will be randomized to one of the two groups:

        -  Experimental group: 90 patients will receive 10 injections of ethanol lock solution in
           implantable venous access port during the first 10 days of the study.

        -  Control group: 90 patients will receive 10 injections of vancomycin lock solution in
           implantable venous access port during the first 10 days of the study.

        -  For each group, in case of bacteraemia, the lock therapy is associated with a systemic
           antibiotic therapy using another venous line and optimized by a specialist in infectious
           diseases.

      Study Performance

      Patients will be assessed at baseline D0, 3 days (D3), 10 days (D10), 14 weeks (W14) after D0
      as follows:

      Visit 1 (D0 - baseline):

        -  Signature of an informed consent form.

        -  Demographic and clinical characteristics (sex, age, disease associated with implantable
           venous access port, implantable venous access port infection data, bacteraemia data)

      Days 1 to 10

        -  Injection of ethanol or vancomycin lock solution in implantable venous access port

        -  Ethanolemia 30 minutes after injection, on first day

        -  Side effects evaluation

      Visit 2 (D3) and Visit 3 (D10)

        -  Side effects evaluation

        -  Blood culture

        -  Bacteraemia data (antibiotic therapy modification)

      Phone contact each week from week 2 to week 13

      End Visit (W14)

        -  Side effects evaluation

        -  Blood culture

        -  Bacteraemia data (antibiotic therapy modification)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery at 12 week following the lock solution treatment completion</measure>
    <time_frame>at 12 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Favorable evolution without complication up to the end of implantable venous access port use</measure>
    <time_frame>at 12 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Favorable evolution without complication until the implantable venous access port withdrawal</measure>
    <time_frame>at 12 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative peripheral and port blood cultures</measure>
    <time_frame>at day 3 and day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality due to infection of the port</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantable venous access port withdrawal rate</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical complication rate</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood alcohol concentration</measure>
    <time_frame>30 min after the first lock solution treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects evaluation</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Lock Solution</condition>
  <condition>Catheter Related Blood Stream Infections</condition>
  <condition>Central Venous Catheter Infection</condition>
  <condition>Intravenous Drug Delivery Systems</condition>
  <condition>Coagulase-negative Staphylococci Infection</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol 40% + Enoxaparine 400UI/ml</intervention_name>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycine 5 mg/ml + Héparine 2500UI/ml</intervention_name>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman from 18 years old

          -  With probable or definite implantable venous access port infection

          -  With or without bacteraemia

          -  Infection due to coagulase-negative staphylococci (except for lugdunensis
             Staphylococci)

          -  Blood culture results available within 48 hours before inclusion

          -  With health insurance

        Exclusion Criteria:

          -  Pregnant or breastfeeding woman

          -  Allergy to ethanol

          -  Patient with prosthetic cardiac valve

          -  Necessity of venous access port withdrawal

          -  Prior infection on the same venous access port

          -  Patients under supervision or (legal) guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier LESENS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier LESENS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lock Solution</keyword>
  <keyword>Catheter related blood stream infections</keyword>
  <keyword>Central venous catheter infection</keyword>
  <keyword>Intravenous Drug Delivery Systems</keyword>
  <keyword>Coagulase-negative staphylococci infection</keyword>
  <keyword>Ethanol lock solution</keyword>
  <keyword>Vancomycin lock solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Coagulase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

